Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

ABSTRACT: Although the transition to molecularly defined patient subgroups in advanced non-small cell lung cancer (NSCLC) often leads to dramatic and prolonged responses to an inhibitor of an identified oncogenic mutation, acquired resistance eventually ensues. The optimal approach to management in that setting remains the subject of ongoing research, although it is possible to identify several points that distinguish it from traditional tenets based on conventional chemotherapy. Such patients are not equivalent to those who have progressed on first-line chemotherapy, and consideration of initiation of chemotherapy-based regimens as if the patient were being treated first line in the absence of an oncogenic mutation is a reasonable consideration. Acquired resistance is often partial; therefore, cont

SUBMITTER: West H 

PROVIDER: S-EPMC4142045 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature